ELIGIBILITY FOR
IMMUNOTHERAPY
Eligibility isn't a single gate you pass or fail. It's a multifactor assessment that differs by agent, cancer type, and molecular profile. This page gives you the framework โ so you can ask the right questions rather than wait to be told what applies.
analyticsAt a Glance
- check_circleBiomarker testing (PD-L1, TMB, MSI) is required to determine likely response to checkpoint inhibitors
- check_circleAutoimmune conditions, organ transplant history, and active infections may exclude patients
- check_circlePerformance status and organ function determine whether a patient can safely receive immunotherapy
- check_circleCancerFax helps patients understand eligibility and find internationally available immunotherapy options
What This Means for Patients
Immunotherapy eligibility isn't a single gate you either pass or don't. It's a multifactor assessment that differs by the specific agent being considered, the cancer type it's approved for, and what your tumor looks like at a molecular level. The same patient can be eligible for one immunotherapy approach and ineligible for another. The same cancer type can make a patient eligible or ineligible depending on which biomarkers are present. General rules don't work here. Specifics do.
Key Eligibility Factors
Six factors consistently determine immunotherapy eligibility assessments โ each independent and each essential.
Cancer Type and Stage
Immunotherapy approvals are indication-specific. Pembrolizumab is approved for certain lung cancers, not all of them. Knowing the exact approved indication for your cancer type and stage is the first filter.
Biomarker Profile
PD-L1 expression, tumor mutational burden (TMB), microsatellite instability (MSI), and mismatch repair (MMR) status are the primary molecular markers guiding checkpoint inhibitor eligibility. Without testing, the eligibility question cannot be answered accurately.
Prior Treatment History
Some regimens are first-line options. Others are approved only after prior lines have failed. What you've received before shapes what's available next โ and affects washout period requirements.
Performance Status
Most immunotherapy programs require ECOG 0 or 1 โ adequate functional capacity to tolerate treatment and attend monitoring visits. Performance status is assessed clinically, not by age.
Organ Function
Liver, kidney, and lung function are assessed before treatment begins. Pre-existing autoimmune conditions require individual evaluation โ active severe autoimmune disease is often a contraindication.
Driver Mutation Status
In lung cancer, EGFR and ALK mutations often shift first-line priority toward targeted therapy. The presence of actionable driver mutations affects the priority ordering for immunotherapy consideration.
Key Biomarker Tests for Immunotherapy Eligibility
The primary molecular tests and what they determine.
| Biomarker | Method | Relevant Immunotherapy | Clinical Significance |
|---|---|---|---|
| PD-L1 Expression | IHC (CPS or TPS score) | PD-1 / PD-L1 checkpoint inhibitors | Guides first-line monotherapy eligibility in NSCLC, urothelial, cervical, and others |
| Tumor Mutational Burden (TMB) | NGS panel | Pembrolizumab (TMB-H approval) | High TMB (โฅ10 mut/Mb) is a tumor-agnostic eligibility criterion |
| MSI / dMMR Status | PCR or IHC | Pembrolizumab, nivolumab, dostarlimab | First-line approval in dMMR/MSI-H CRC; tumor-agnostic pembrolizumab approval |
| EGFR / ALK Mutations | NGS or FISH | Affects checkpoint inhibitor priority | Presence typically shifts first-line priority to targeted therapy in NSCLC |
| HER2 / EGFR / CD20 | IHC or NGS | Monoclonal antibody eligibility | Required target expression for trastuzumab, cetuximab, rituximab, and ADC candidates |
Who This Is Relevant For
Every patient for whom immunotherapy has been mentioned as a possibility โ or who wants to know whether it should be. Understanding the eligibility factors transforms the conversation from 'am I eligible?' to asking specifically: has my tumor been tested for PD-L1? What's my TMB? Has MSI status been assessed? Those specific questions get specific answers.
Benefits and Limitations
Benefits of Early Testing
- Transforms the clinical conversationKnowing your biomarker profile means you ask informed questions rather than waiting to be told what's available.
- Creates real optionsTesting at diagnosis rather than in urgency opens more treatment pathways and allows proper sequence planning.
- Age is rarely a barrierPatients in their 70s and 80s have received immunotherapy. Performance status matters far more than chronological age.
Limitations to Know
- Eligibility criteria evolveApprovals expand regularly. What was not an option six months ago may be one now โ requiring a specialist who actively tracks the landscape.
- One test is rarely enoughPD-L1 alone does not answer the eligibility question. Comprehensive NGS panels are increasingly the standard.
- Autoimmune conditions require individual assessmentPre-existing autoimmune disease is not automatically disqualifying but requires careful evaluation and closer monitoring.
When to Consider This Option
Biomarker testing should happen at diagnosis for most cancer types where immunotherapy is established โ not when a treatment decision becomes urgent. Test early. Understand the results. That's what creates real options rather than theoretical ones.
Frequently Asked Questions
Eligibility Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Not Sure if Your Tumor Has Been Tested for Immunotherapy Eligibility?
Eligibility starts with biomarker testing โ PD-L1, TMB, and MSI status. Upload your pathology reports and our specialist team will assess what molecular data is available and what further testing may be needed.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.